• British Pharmacopoeia Volume I & II
  • Monographs: Medicinal and Pharmaceutical Substances

Ketotifen Fumarate

European Union chaplet of stars
scroll to previous hit
scroll to next hit
General Notices

(Ketotifen Hydrogen Fumarate, Ph  Eur  monograph  1592)

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_1_2009_60_cs.png


C19H19NOS,C4H4O4    425.5    34580-14-8

Action and use

Histamine H1 receptor antagonist.

Ph Eur

DEFINITION

4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one hydrogen (E)-butenedioate.

Content

98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS
Appearance

White to brownish-yellow, fine, crystalline powder.

Solubility

Sparingly soluble in water, slightly soluble in methanol, very slightly soluble in acetonitrile.

IDENTIFICATION

A.  Infrared absorption spectrophotometry (2.2.24).

Comparison  Ph. Eur. reference spectrum of ketotifen hydrogen fumarate.

B.  Thin-layer chromatography (2.2.27).

Test solution  Dissolve 40 mg of the substance to be examined in methanol R and dilute to 10 ml with the same solvent.

Reference solution  Dissolve 11 mg of fumaric acid CRS in methanol R and dilute to 10 ml with the same solvent.

Plate  cellulose for chromatography F254 R as the coating substance.

Mobile phase  water R, anhydrous formic acid R, di-isopropyl ether R (3:7:90 V/V/V).

Application  5 µl.

Development  Over a path of 17 cm.

Drying  In a current of warm air.

Detection  Examine in ultraviolet light at 254 nm. Spray lightly with a 5 g/l solution of potassium permanganate R in a 1.4 per cent V/V solution of sulphuric acid R. Examine in daylight by transparency.

Results  The spot due to fumaric acid in the chromatogram obtained with the test solution is similar in position, colour and intensity to the principal spot in the chromatogram obtained with the reference solution.

TESTS
Appearance of solution

The solution is clear (2.2.1) and not more intensely coloured than reference solution Y4, BY4 or B4 (2.2.2, Method II).

Dissolve 0.2 g in methanol R and dilute to 10 ml with the same solvent.

Related substances

Liquid chromatography (2.2.29).

Test solution  Dissolve 30.0 mg of the substance to be examined in a mixture of equal volumes of methanol R and water R and dilute to 100.0 ml with the same mixture of solvents.

Reference solution (a)  Dilute 1.0 ml of the test solution to 50.0 ml with a mixture of equal volumes of methanol R and water R. Dilute 1.0 ml to 10.0 ml with a mixture of equal volumes of methanol R and water R.

Reference solution (b)  Dissolve 3.0 mg of ketotifen impurity G CRS in 10 ml of methanol R and dilute to 20.0 ml with water R. Protect the solution from light.

Reference solution (c)  To 1.5 ml of reference solution (b) add 1.0 ml of the test solution and dilute to 10.0 ml with a mixture of equal volumes of methanol R and water R. Protect the solution from light.

Reference solution (d)  Dilute 0.5 ml of reference solution (b) to 50.0 ml with a mixture of equal volumes of methanol R and water R. Protect the solution from light.

Column:
  • size: l  =  0.15 m, Ø  =  4.0 mm;
  • temperature: 40 °C.
Mobile phase:

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_2_2009_60_tb.png


Flow rate  1.0 ml/min.

Detection  Spectrophotometer at 297 nm.

Injection  20 µl; inject the test solution and reference solutions (a), (c) and (d).

Relative retentions with reference to ketotifen: impurity D  =  about 0.31; impurity C  =  about 0.61; impurity G  =  about 0.86; impurity E  =  about 1.18; impurity F  =  about 1.36; impurity B  =  about 1.72; impurity A  =  about 2.15.

System suitability:
  • resolution: minimum of 1.5 between the peaks due to ketotifen and to impurity G in the chromatogram obtained with reference solution (c);
  • signal-to-noise ratio: minimum of 70 for the principal peak in the chromatogram obtained with reference solution (d).
Limits:
  • correction factor: for the calculation of contents, multiply the area of the corresponding peak by the following correction factor: impurity G  =  1.36;
  • impurity G: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);
  • any impurity: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);
  • total: not more than 2.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
  • disregard limit: 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 4 h.

Maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.350 g in a mixture of 30 ml of anhydrous acetic acid R and 30 ml of acetic anhydride R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).

1 ml of 0.1 M perchloric acid is equivalent to 42.55 mg of C23H23NO5S.

IMPURITIES

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_3_2009_60_cs.png


A.  4-(4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidine,

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_4_2009_60_cs.png


B.  (4RS)-10-methoxy-4-(1-methylpiperidin-4-yl)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ol,

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_5_2009_60_cs.png


C.  (4RS)-4-hydroxy-4-(1-methylpiperidin-4-yl)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one,

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_6_2009_60_cs.png


D.  4-[(aRaS)-1-methylpiperidin-4-ylidene]-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one N-oxide (ketotifen N-oxide),

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_7_2009_60_cs.png


E.  10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one,

bp2010_v2_01_monographs_medicinal_and_pharmaceutical_substances ketotifenhydrogenfumarate_8_2009_60_cs.png


F.  X  =  H2: 4-(1-methylpiperidin-4-ylidene)-4,10-dihydro-9H-benzo[4,5]cyclohepta[1,2-b]thiophen-9-one,

G.  X  =  O: 4-(1-methylpiperidin-4-ylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-9,10-dione.

Ph Eur